News | Hypertension | December 27, 2018

Barbershop Intervention Continues to Lower Blood Pressure at One Year

Reductions in systolic blood pressure observed at 6 months in Cedars-Sinai study were sustained at 12 months

Barbershop Intervention Continues to Lower Blood Pressure at One Year

December 27, 2018 — African-American men participating in a blood pressure reduction program implemented in barbershops continued to have significant improvements in their blood pressure in a twelve-month follow-up study. The research was published in the American Heart Association journal Circulation.1

In the study led by Cedars-Sinai’s Smidt Heart Institute, 52 Los Angeles County barbershops were assigned to either a pharmacist-led intervention or an active control group. In the intervention group, barbers measured blood pressure and promoted follow-up with pharmacists who prescribed blood pressure medication under a collaborative practice agreement with study participants’ primary care providers. In the control group, barbers measured blood pressure and promoted follow-up only with primary care providers and lifestyle modification. At 6 months, the men in the intervention group had significant reductions in their blood pressure compared to those in the control group.

Read the article "Managing Blood Pressure in Barbershops Yields Substantial Improvements" 

After six months, the intervention group continued the program, but had fewer in-person pharmacist visits to test if the intervention effect could be sustained safely for one year while reducing pharmacist travel time to and from barbershops.

When the study began, participants had an average systolic blood pressure of 152.4 mm Hg in the intervention group and 154.6 mm Hg in the control group. Systolic blood pressure is the top number in a blood pressure reading and it measures the pressure the blood exerts against the arteries while the heart is pumping.

At 12 months, the average systolic blood pressure fell by 28.6 mm Hg (to 123.8 mm Hg) in the intervention group and by 7.2 mm Hg (to 147.4 mm Hg) in the control group. The average reduction was 20.8 mm Hg greater with the intervention. These results are indistinguishable from the previously reported 6-month data, which were published in the New England Journal of Medicine.2

The principal investigator for the study was the late Ronald G. Victor, M.D., associate director of the Smidt Heart Institute. In 2010, Victor became the first to prove, through randomized, controlled testing, that barbershop-based health programs could potentially save hundreds of lives annually by helping African American men lower their blood pressure.

Watch the VIDEO: Reducing Hypertension Among African-Americans

For more information: www.ahajournals.org/journal/circ

References

1. Victor R.G., Blyler C.A., Li N., et al. Sustainability of Blood Pressure Reduction in Black Barbershops. Circulation, Dec. 17, 2018. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.038165

2. Victor R.G., Lynch K., Li N., et al. A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops. New England Journal of Medicine, April 5, 2018. DOI: 10.1056/NEJMoa1717250


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now